Abingworth llp - see note investment history in Proteon therapeutics inc

Filed on 2014-10-29 by Abingworth Llp SEC CIK 1397144 Form 4

Accession 0000905718-14-000703.txt Sec File: edgar/data/1397144/0000905718-14-000703-index.htm

2014-10-27 Abingworth Llp (CIK 1397144) through See Note

Invested in Proteon Therapeutics Inc sold 12835264 shares remaining shares owned 0

Option Right To Purchase Proteon Therapeutics Inc Prto underlying security shares 808775 underlying security title Series D Convertible Preferred Stock

f5 abingworth had a right to purchase shares of series d convertible preferred stock under the series d purchase agreement at a price of $0.588656, which right to purchase ceased to be exercisable upon the initial filing of the issuer's registration statement for its initial public offering, and terminated upon the completion of the issuer's initial public offering of common stock. each share of series d preferred stock issuable upon exercise of the right to purchase would have been convertible into shares of the issuer's common stock as described in footnote (3) above.
f2 the shares are held by abingworth bioventures vi, lp ("abingworth"). abingworth bioventures vi gp lp ("abingworth gp") serves as the general partner of abingworth. abingworth general partner vi llp, serves as the general partner of abingworth gp. abingworth (acting by its general partner abingworth gp, acting by its general partner abingworth general partner vi llp) has delegated to abingworth llp, all investment and dispositive power over the securities held by abingworth. the reporting person holds the reported securities indirectly through abingworth. the reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. this report shall not be deemed an admission that the reporting person, abingworth or any other person is the beneficial owner of the securities reported herein for purposes of section 16 of the securities exchange act of 1934, as amended, or for any other purpose.
f4 reflects a 1-for-15.87 reverse stock split effected on october 6, 2014.


Filed on 2014-10-29 by Abingworth Llp SEC CIK 1397144 Form 4

Accession 0000905718-14-000703.txt Sec File: edgar/data/1397144/0000905718-14-000703-index.htm

2014-10-27 Abingworth Llp (CIK 1397144) through See Note

Invested in Proteon Therapeutics Inc sold 16044081 shares remaining shares owned 0

Series D Convertible Preferred Stock Proteon Therapeutics Inc Prto underlying security shares 1010969 underlying security title Common Stock

f3 upon the closing of the issuer's initial public offering, each share of series d convertible preferred stock automatically converted into common stock on a one-for-one basis (without payment of further consideration and with no expiration date) plus an additional 56,903 incremental shares as a result of an adjustment as provided for in the company's certificate of incorporation.
f2 the shares are held by abingworth bioventures vi, lp ("abingworth"). abingworth bioventures vi gp lp ("abingworth gp") serves as the general partner of abingworth. abingworth general partner vi llp, serves as the general partner of abingworth gp. abingworth (acting by its general partner abingworth gp, acting by its general partner abingworth general partner vi llp) has delegated to abingworth llp, all investment and dispositive power over the securities held by abingworth. the reporting person holds the reported securities indirectly through abingworth. the reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. this report shall not be deemed an admission that the reporting person, abingworth or any other person is the beneficial owner of the securities reported herein for purposes of section 16 of the securities exchange act of 1934, as amended, or for any other purpose.
f4 reflects a 1-for-15.87 reverse stock split effected on october 6, 2014.


Filed on 2014-10-29 by Abingworth Llp SEC CIK 1397144 Form 4

Accession 0000905718-14-000703.txt Sec File: edgar/data/1397144/0000905718-14-000703-index.htm

2014-10-27 Abingworth Llp (CIK 1397144) through See Note

Invested in Proteon Therapeutics Inc bought 1067872 shares remaining shares owned 2017872

Common Stock Proteon Therapeutics Inc Prto Transaction code: C Conversion of derivative security (usually options)

f3 upon the closing of the issuer's initial public offering, each share of series d convertible preferred stock automatically converted into common stock on a one-for-one basis (without payment of further consideration and with no expiration date) plus an additional 56,903 incremental shares as a result of an adjustment as provided for in the company's certificate of incorporation.


Filed on 2014-10-29 by Abingworth Llp SEC CIK 1397144 Form 4

Accession 0000905718-14-000703.txt Sec File: edgar/data/1397144/0000905718-14-000703-index.htm

2014-10-27 Abingworth Llp (CIK 1397144) through See Note

Invested in Proteon Therapeutics Inc bought 950000 shares at $10.00 remaining shares owned 950000

Common Stock Proteon Therapeutics Inc Prto Transaction code: P Open market or private purchase of securities

f1 these shares were purchased in connection with the issuer's initial public offering of common stock.
f2 the shares are held by abingworth bioventures vi, lp ("abingworth"). abingworth bioventures vi gp lp ("abingworth gp") serves as the general partner of abingworth. abingworth general partner vi llp, serves as the general partner of abingworth gp. abingworth (acting by its general partner abingworth gp, acting by its general partner abingworth general partner vi llp) has delegated to abingworth llp, all investment and dispositive power over the securities held by abingworth. the reporting person holds the reported securities indirectly through abingworth. the reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. this report shall not be deemed an admission that the reporting person, abingworth or any other person is the beneficial owner of the securities reported herein for purposes of section 16 of the securities exchange act of 1934, as amended, or for any other purpose.